Carmustine decreases amyloid beta plaques

March 25, 2013

Long term treatment by carmustine, a chemical relative of mustard gas and already used to treat some types of brain cancer, can decrease the amount of amyloid β and number of amyloid plaques in a mouse model of Alzheimer's disease. The research is published in Biomed Central's open access journal BMC Medicine.

Alzheimer's disease progressively destroys memory, language, and judgement of affected people. While deaths due to heart disease, stroke and cancer may be decreasing, the number of deaths each year due to Alzheimer's disease is on the increase. Accumulation of amyloid β plaques can be seen in the brain from early stages, even though the exact relationship between these plaques and Alzheimer's disease has not yet been firmly established.

Noticing that people with cancer tended not to get Alzheimer's disease, and vice versa, researchers from the Florida based Torrey Pines Institute for Molecular Studies screened a library of all FDA approved anti- for their ability to reduce amyloid β levels in cells expressing amyloid . From this screen they found that carmustine could decrease conversion of precursor protein to amyloid β levels by 60%.When tested in a mouse model of Alzhiemer's disease, long term treatment with carmustine was able to reduce amyloid β levels by 75%.

Discussing how this research could translate to humans Dr Madepalli Lakshmana, who led this study commented, "The level of carmustine needed to achieve reduction in amyloid β is much lower than the dose already used in the treatment of some types of brain cancer. Also carmustine does not appear to act by activating or by blocking secretases which reduces possible side effects seen with other anti-amyloid investigational . While more work still needs to be done carmustine appears to be a powerful candidate drug for treatment and prevention of Alzheimer's disease."

Explore further: Road block as a new strategy for the treatment of Alzheimer's

More information: Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine Crystal D Hayes, Debleena Dey, Juan Pablo Palavicini, Hongjie Wang, Kshitij A Patkar, Dmitriy Minond, Adel Nefzi and Madepalli K Lakshmana BMC Medicine 2013, 11:81 doi:10.1186/1741-7015-11-81

Commentary: Potential repurposing of oncology drugs for the treatment of Alzheimer's disease, Wataru Araki BMC Medicine 2013, 11:82 doi:10.1186/1741-7015-11-82

Related Stories

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011

Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Researchers identify new enzyme to fight Alzheimer's disease

September 17, 2012

An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme—known as BACE2—destroys beta-amyloid, a toxic protein fragment ...

Recommended for you

Alzheimer's stemmed but not stopped, say experts

September 19, 2016

Soaring rates of population growth and ageing have long been seen as portending a global explosion of Alzheimer's, the debilitating disease that robs older people of their memory and independence.

Memory loss not enough to diagnose Alzheimer's

September 13, 2016

Relying on clinical symptoms of memory loss to diagnose Alzheimer's disease may miss other forms of dementia caused by Alzheimer's that don't initially affect memory, reports a new Northwestern Medicine study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.